The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Reading through Eli Lilly news from today , there is a report with the following three paragraphs....the last one may hold a clue to where we are... who knows
The drug, which Lilly licensed from Incyte, works by inhibiting JAK1 and JAK2, thereby controlling inflammation in arthritis patients. The hope is that the same mechanism could be helpful in treating COVID-19.
Patrik Jonsson, president of Lilly Bio-Medicines, told FiercePharma that Olumiant could represent a “very important first step” toward reducing mortality for patients hospitalized with COVID-19.
“It’s not going to be the final step,” he said. Instead, antibody therapies or vaccines would represent that "final step" toward defeating COVID-19, Jonsson said. Lilly has started two antibody trials in recent weeks.
https://www.fiercepharma.com/pharma/lilly-starts-testing-arthritis-med-olumiant-covid-19-alongside-antibody-works
Manifesto
Once the target company is notified of a takeover offer, it should immediately issue an announcement giving the terms and conditions of the offer. This might either be for cash, or for shares with a cash alternative. Trading of the company’s shares may be temporarily suspended pending the announcement...... just quoting what potentially happens.
Has Vlad been approached for a takeover? Is this what the announcement could be about? Are we being informed of the terms and conditions?
If Vlad is offered a buyout for £500 million and we have have 434 million shares in issue we can all see the maths here, if it's a £billion buyout equate that to the number of shares you hold. Could be that his news is a buyout or a mixture of shares and cash or production trial of Covid 19 vaccine . Possibly company suspension of share trading tomorrow until the deal is done, many scenario's to ponder over the next 21 hours.
BioNTech and Pfizer’s Covid-19 vaccine trial yields positive results
Financial Times yesterday
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/65d0b33a-f12a-4878-ac87-da4835683949
A coronavirus vaccine from Germany’s BioNTech has yielded positive trial results, generating immune defences in participants that were stronger than those of the average recovered Covid-19 patient, according to preliminary data released by the company.
In a clinical study run with pharmaceuticals group Pfizer in the US, 24 people between the ages of 18 and 55 who received two doses of the vaccine had “significantly elevated” antibodies within four weeks of their first injection.
https://www.ft.com/content/65d0b33a-f12a-4878-ac87-da4835683949
One to work on today from research ...... June 20th 2020...... any links to Hemogenyx on this approval
FDA Approves Epizyme's Tazverik, Roche CDx for EZH2-Mutated Follicular Lymphoma Patients
Jun 18, 2020 |
NEW YORK – The US Food and Drug Administration granted accelerated approval on Thursday to Epizyme's tazemetostat (Tazverik) for relapsed or refractory follicular lymphoma patients with an EZH2 mutation as detected by an FDA approved test.
The FDA also approved the Cobas EZH2 Mutation Test by Roche as a companion diagnostic for tazemetostat.
The approval was based on data from two single-arm cohorts of a study involving patients with pretreated follicular lymphoma. In the study, EZH2 mutations were identified prospectively in patients' tumor samples using the Cobas EZH2 Mutation test.
Agree Pingu, I would think we have the mice on equal grounds to the Duracel battery, interesting to see that another company was bought out for £2.3 billion pounds in 2007, what a great advancement for science (far beyond me but great for T1 diabetes sufferers like me if they can replace good cells for the bad ones), even better if the Covid 19 trials progress further.
How much are mice worth ? Take a look at this article to see where Hemogenyx are heading, these are actual companies especially one that was bought out for £2.2 Billion.... you'll need an hour to digest the material, "it's a long tail".
Mice With The Human Touch
nature.com/articles/nbt1007-1075?draft=marketing
So if we already have links with J&J in the form of a collaboration (Lupus) also with using the humanised mice, what is there to say that behind the scenes this has been expanded to include the Covid 19 trials that J&J are progressing at a fast rate, could they be the silent company that does not wish to say to much at the moment?
Total Shares 433,636,255
states 50.01% not in public hands (unless there are a lot of 3%'s or below)
Listed know holders
Craig Auringer 23,837,250 5.50%
Alexis Sandler 75,090,685 17.32%
Dr Vladislav Sandler 41,544,677 9.58%
Peter Redmond 5,596,270 1.29%
Samantha Bauer 17,996,487 4.15%
Mark Hawtin 12,668,570 2.92%
Great 50th birthday investment by Craig Auringer
Some interesting names to work on especially good old Peter Redmond,
Mr Geoffrey Gilbert Dart Director Mar 1947 13 Feb 2013 04 Oct 2017
Mr Timothy Vincent Le Druillenec Company Secretary - 14 Nov 2013 30 Nov 2017
Mr Timothy Vincent Le Druillenec Director Nov 1957 13 Nov 2014 29 Jul 2015
MR PETER REDMOND Director Jul 1946 29 Jul 2015 -
Mr Adrian Richard Thorpe Beeston Director Aug 1969 29 Jul 2015 09 Apr 2018
MS ALEXIS SANDLER Director Mar 1976 04 Oct 2017 -
DR VLADISLAV SANDLER Director Aug 1965 04 Oct 2017 -
Mr Timothy Vincent Le Druillenec Director Nov 1957 04 Oct 2017 30 Nov 2017
Mr Lawrence Pemble Director May 1988 04 Oct 2017 05 Nov 2018
Dr Robin William Campbell Director Sep 1956 04 Oct 2017 05 Jan 2019
SIR MARC FELDMANN Director Dec 1944 09 Apr 2018 -
MR ANDREW WRIGHT Company Secretary - 05 Nov 2018
Who's in , Who's out
Just breakfast reading before the markets open.... worth it's time.... this is where it mentions "humanized mouse model" , is this where we come in under joint venture, date of article is June 10th 2020
https://www.globenewswire.com/news-release/2020/06/10/2046273/0/en/Orgenesis-Announces-Anti-Viral-BioShield-Program-Designed-to-Potentially-Increase-Preparedness-Rapidly-Address-Virus-Spread-and-Protect-Against-Future-Outbreaks-such-as-COVID-19.html
It's been a number of years since I last involved myself in shares, the days of Oxus Gold which turned to dust before my eyes...... WOW Hemogenyx has awakened my interest, cutting through all the usual "carp" up down in out and sticking to research.
Looking back at 2019 with the interest from Orgenesis and using their quote of it's rapidly expanding global joint ventures including Hemo it states "The company plans to leverage its IP, technical and
manufacturing competencies to establish a closed system manufacturing
approach for their development stage product". Would the tie in with this company have significant knowledge through Hemo's humanised mice to speed up development in the Covid 19 vaccine.
Will the cat emerge from the bag and kill the mice or will the mice dominate and scare away the cat..... who know's?